Share Twitter LinkedIn Facebook Email Dr. Nima Sharifi, MD of Cleveland Clinic answers the question How does CYP17 inhibitors and novel androgen receptor inhibitors affect current treatment paradigms for advanced prostate cancer at ASCO GU 2016 in San Francisco.
ASH 2025 MDS/ALL Highlights: Verona Trial Lessons & CLEVER Pathway | Dr. Jeyakumar Acute Lymphoblastic Leukemia 5 Mins Read
Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani Acute Lymphoblastic Leukemia 3 Mins Read